Skip to main content

Main menu

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Blog
    • Collections
    • Podcast
  • TOPICS
    • Cognition and Behavior
    • Development
    • Disorders of the Nervous System
    • History, Teaching and Public Awareness
    • Integrative Systems
    • Neuronal Excitability
    • Novel Tools and Methods
    • Sensory and Motor Systems
  • ALERTS
  • FOR AUTHORS
  • ABOUT
    • Overview
    • Editorial Board
    • For the Media
    • Privacy Policy
    • Contact Us
    • Feedback
  • SUBMIT

User menu

Search

  • Advanced search
eNeuro

eNeuro

Advanced Search

 

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Blog
    • Collections
    • Podcast
  • TOPICS
    • Cognition and Behavior
    • Development
    • Disorders of the Nervous System
    • History, Teaching and Public Awareness
    • Integrative Systems
    • Neuronal Excitability
    • Novel Tools and Methods
    • Sensory and Motor Systems
  • ALERTS
  • FOR AUTHORS
  • ABOUT
    • Overview
    • Editorial Board
    • For the Media
    • Privacy Policy
    • Contact Us
    • Feedback
  • SUBMIT
PreviousNext
Research ArticleNegative Results, Disorders of the Nervous System

Hypoxia Inducible Factor-1α in Astrocytes and/or Myeloid Cells Is Not Required for the Development of Autoimmune Demyelinating Disease

Natacha Le Moan, Kim M. Baeten, Victoria A. Rafalski, Jae Kyu Ryu, Pamela E. Rios Coronado, Catherine Bedard, Catriona Syme, Dimitrios Davalos and Katerina Akassoglou
eNeuro 30 March 2015, 2 (2) ENEURO.0050-14.2015; DOI: https://doi.org/10.1523/ENEURO.0050-14.2015
Natacha Le Moan
1Gladstone Institute of Neurological Disease, University of California, San Francisco, San Francisco, CA 94158, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kim M. Baeten
1Gladstone Institute of Neurological Disease, University of California, San Francisco, San Francisco, CA 94158, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kim M. Baeten
Victoria A. Rafalski
1Gladstone Institute of Neurological Disease, University of California, San Francisco, San Francisco, CA 94158, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jae Kyu Ryu
1Gladstone Institute of Neurological Disease, University of California, San Francisco, San Francisco, CA 94158, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pamela E. Rios Coronado
1Gladstone Institute of Neurological Disease, University of California, San Francisco, San Francisco, CA 94158, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catherine Bedard
1Gladstone Institute of Neurological Disease, University of California, San Francisco, San Francisco, CA 94158, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catriona Syme
1Gladstone Institute of Neurological Disease, University of California, San Francisco, San Francisco, CA 94158, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Catriona Syme
Dimitrios Davalos
1Gladstone Institute of Neurological Disease, University of California, San Francisco, San Francisco, CA 94158, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katerina Akassoglou
1Gladstone Institute of Neurological Disease, University of California, San Francisco, San Francisco, CA 94158, USA
2Department of Neurology, University of California, San Francisco, San Francisco, CA 94143, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1

    Stabilization and transcriptional activation of HIF-1α in the spinal cord of EAE mice. A, Western blot for HIF-1α in spinal cords of control (n = 3), pre-onset EAE, day 7 postimmunization (p.i.; n = 3) and peak EAE, day 16 p.i. (n = 3) mice. Normoxic (21% O2) and hypoxic (10% O2) brain extracts were loaded with spinal cord extracts of EAE mice to demonstrate HIF-1α protein stabilization. β-Actin-loading controls were performed on the same membrane. N, Normoxia; H, hypoxia. ANOVA: p = 0.002 a . Peak EAE had a higher ratio of HIF-1α/β-actin than control (p = 0.006 a ) or pre-onset EAE mice (p = 0.003 a ). B, Quantitative real-time PCR analysis of HIF-1α expression in spinal cords of control (n = 3) and peak EAE (n = 3) mice, p = 0.01 b . C, Quantitative real-time PCR analysis of HIF-1α target genes iNOS and EPO in spinal cords of control (n = 3) and peak EAE (n = 3) mice, p = 0.03 c and p = 0.04 d . D, Quantitative analysis of photon emission in spinal cord of HIF-1αluc control (n = 3) and peak EAE mice with MOG/CFA/PTX (n = 12) or CFA/PTX (n = 15). ANOVA: p = 0.00004 e . MOG/CFA/PTX had greater bioluminescence than both CFA/PTX (p = 0.0005 e ) and control mice (p = 0.0005 e ). HIF-1αluc mice were killed and spinal cord tissues were excised to extract proteins. The bioluminescence signal was quantified ex vivo by the luciferase assay and expressed as RLUs per OD of proteins at 600 nm. Data are presented as mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001 by Holm’s test in B and C, and one-way ANOVA followed by Tukey multiple comparisons in A and D . Superscript letters refer to the statistical results in Tables 1, 2, and Results.

  • Figure 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2

    HIF-1α is expressed in astrocytes and microglia/macrophages in the spinal cord of EAE mice. A, Immunohistochemical staining for HIF-1α in spinal cord sections from healthy mice and at peak EAE, 17 d p.i. Absorption control after anti-HIF-1α antibody incubation with HIF-1α blocking peptide at peak EAE. Scale bar, 300 μm. Arrows indicate neuronal cells. B, Higher-magnification of HIF-1α immunostaining in the grey and white matter of the spinal cord of healthy and EAE mice. Scale bar, 50 μm. Arrows indicate neuronal cells. C, Double-immunofluorescence with antibodies against HIF-1α (green) and GFAP (top) or isoB4 (bottom) (red) of spinal cord sections of EAE mice 17 d after immunization. Scale bar, 50 μm. Arrows indicate HIF-1α+isoB4– cells with astrocyte-like morphology (green).

  • Figure 3
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3

    Genetic depletion or overexpression of HIF-1α in myeloid cells does not affect the clinical course of EAE, demyelination, and inflammatory infiltrates. A, Clinical scores of mice genetically depleted for HIF-1α in myeloid cells lysM-Cre:HIF-1αfl/fl (n = 17) and control mice HIF-1αfl/fl (n = 22). B, Clinical scores of mice overexpressing HIF-1α in microglia/macrophages lysMCre:VHLfl/fl (n = 20) and control mice VHLfl/fl (n = 15). A and B, For each genotype, day of onset, maximum clinical score, and percentage of mice developing signs of paralysis (score ≥3) were calculated using mixed linear effects models, and the results are presented in Table 1. Data are presented as mean ± SEM. C, LFB/PAS staining shows demyelination in HIF-1αfl/fl (n = 5) and lysM-Cre:HIF-1αfl/fl (n = 5). Data are presented as mean ± SEM. Statistical analysis was performed using the unpaired t test (p = 0.28 l ). D, Immunohistochemistry for CD3 shows no significant differences in inflammation between HIF-1αfl/fl (n = 5) and lysM-Cre:HIF-1αfl/fl (n = 5). Data are expressed as number of CD3+ cells/mm2 per mouse and presented as mean ± SEM. Statistical analysis was performed using the unpaired t test (p = 0.14 m ). E, Immunohistochemistry for Mac-2 shows no significant differences in inflammation between HIF-1αfl/fl (n = 4) and lysM-Cre:HIF-1αfl/fl (n = 4). Data are expressed as percentage of Mac-2+ area per mouse and presented as mean ± SEM. Statistical analysis was performed using unpaired t test (p = 0.153 n ). Superscript letters refer to the statistical results in Tables 1, 2, and Results.

  • Figure 4
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4

    Genetic depletion of HIF-1α in astrocytes decreases expression of HIF-1α and iNOS in astrocytes. A, Staining for HIF-1α in GFAP-Cre:HIF-1αfl/fl and HIF-1αfl/fl mice after EAE. B, Quantification of iNOS expression in Mac-2+ macrophages and GFAP-expressing astrocytes at peak EAE in HIF-1αfl/fl mice (n = 5). Area = 0.056 mm2. Data are presented as mean ± SEM from n = 5 mice. Statistical analysis was performed using an unpaired t-test with Welch’s correction (p = 0.003 ° ). C, Quantification iNOS+ cells at peak EAE in HIF-1αfl/fl (n = 5) and GFAP-Cre:HIF-1αfl/fl (n = 4) mice. Area = 0.056 mm2. Data are presented as mean ± SEM. (continued on page 10). Statistical analysis was performed an unpaired t test (p = 0.034 p ). D, Double-immunofluorescence of GFAP (green) and iNOS (red) in HIF-1αfl/fl and GFAP-Cre:HIF-1αfl/fl mice at peak EAE. Statistical analysis was performed using an unpaired t test (p = 0.01 q ). E, Quantification of iNOS+ GFAP+ cells reveals reduced iNOS-expressing astrocytes in GFAP-Cre:HIF-1αfl/fl (n = 4) compared with HIF-1αfl/fl (n = 5) mice. Area = 0.056 mm2. Statistical analysis was performed using an unpaired t test (p = 0.0159 q ). F, Quantification of GFAP+ astrocytes shows similar numbers of astrocytes in GFAP-Cre:HIF-1αfl/fl (n = 4) and HIF-1αfl/fl (n = 5) mice at peak EAE. Area = 0.056 mm2. Data are presented as mean ± SEM. Statistical analysis was performed using an unpaired t test (p = 0.06 r ). Superscript letters refer to the statistical results in Tables 1, 2, and Results.

  • Figure 5
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5

    Genetic depletion of HIF-1α in astrocytes or in both astrocytes and myeloid cells does not affect the clinical course of EAE. A, Clinical scores of mice genetically depleted for HIF-1α in astrocytes GFAP-Cre:HIF-1αfl/fl (n = 24) and control mice HIF-1αfl/fl (n = 27). B, Clinical scores of mice genetically depleted for HIF-1α in astrocytes and myeloid cells GFAP-Cre:lysM-Cre:HIF-1αfl/fl (n = 16) and control mice HIF-1αfl/fl (n = 13). A and B, For each genotype, day of onset, maximum clinical score, and percentage of mice developing signs of paralysis were calculated using mixed linear effects models, and the results are presented in Table 1. Data are presented as mean ± SEM. C, Immunostaining for tomato-lectin shows no significant differences in lectin+ vessels between HIF-1αfl/fl (n = 5), lysM-Cre:HIF-1αfl/fl (n = 5), and GFAP-Cre:HIF-1αfl/fl (n = 4) at peak EAE. Data are expressed as percentage of lectin+ area per mouse and presented as mean ± SEM. Statistical analysis was performed using one-way ANOVA (p = 0.83 y ). Superscript letter refers to the statistical results in Tables 1, 2, and Results.

Tables

  • Figures
    • View popup
    Table 1

    Quantification of day of onset, clinical score, and paralysis in EAE experiments

    ExperimentGenotypeMice, nDay of onset (95% CI)pMaximum clinical score(95% CI)pParalysis, %p
    1lysM-Cre:HIF-1αfl/fl1711.7 (11.0–12.5)0.77f2.71 (2.43–2.98)0.77g23.50.73h
    HIF-1αfl/fl2211.4 (11.0–12.0)2.79 (2.54–3.02)31.8
    2lysM-Cre:VHLfl/fl207.95 (7.0–9.5)0.90i2.95 (2.32–3.52)0.90j500.99k
    VHLfl/fl 158.56 (7.0–10.0)2.82 (2.15–3.47)46.7
    3GFAP-Cre:HIF-1αfl/fl 2411.40 (11.0–12.0)0.99 s 2.81 (2.43–3.17)0.99 t 62.50.78 u
    HIF-1αfl/fl 2711.29 (11.0–12.0)2.96 (2.64–3.26)55.6
    4GFAP-Cre:lysM-Cre:HIF-1αfl/fl 1611.44 (10.5–12.0)0.65 v 2.56 (2.26–2.88)0.98 w 12.50.19 x
    HIF-1αfl/fl 1311.98 (11.5–12.5)2.57 (2.27–2.86)38.5
    • Experiment 1: EAE induction in lysM-Cre:HIF-1αfl/fl versus control mice HIF-1αfl/fl. Experiment 2: EAE induction in lysMCre:VHLfl/fl versus control mice VHLfl/fl . Experiment 3: EAE induction in GFAP-Cre:HIF-1αfl/fl versus control mice HIF-1αfl/fl . Experiment 4: EAE induction in GFAP-Cre:lysM-Cre:HIF-1αfl/fl versus control mice HIF-1αfl/fl . Day of onset defined as the first day that the score is ≥0.5. A linear mixed-effects model was used to estimate means and 95% confidence interval (CI) for both day of onset and maximum clinical score for each genotype group. A Fisher’s exact test was used to determine whether there is a significant relationship between genotype and mice that achieve score 3 or higher during the experiment (percentage paralysis). Superscript letters refer to the statistical results in Figures 3A, 3B, 5A and 5B. Results, and Table 2.

    • View popup
    Table 2

    Statistical table

    Data structureType of testPower
    aNatural log of HIF1 alpha protein has a normal and homoscedastic distribution and was used as outcome variableANOVA followed by Tukey multiple comparisons of meansPeak EAE vs control = 0.99;Peak EAE vs pre-onset EAE = 0.999;Pre-onset EAE vs Control = 0.10
    bNormal distributionHolm’s test0.911
    cNormal distributionHolm’s test>0.99
    dNormal distributionHolm’s test0.89
    eNatural log of luciferase activity has a normal and homoscedastic distribution and was used as outcome variableANOVA followed by Tukey multiple comparisons of meansCFA+PTX vs control = 0.37;MOG+CFA+PTX vs control = 0.99;MOG+CFA+PTX vs CFA+PTX = 0.99
    fNon-normal distributionMixed-effects model0.64
    gNon-normal distributionMixed-effects model0.17
    hNon-normal distributionFisher’s exact test0.06
    iNon-normal distributionMixed-effects model0.46
    jNon-normal distributionMixed-effects model0.08
    kNon-normal distributionFisher’s exact test0.05
    lNormal distributionStudent’s t test0.18
    mNormal distributionStudent’s t test0.30
    nNormal distributionStudent’s t test0.26
    oNormal distributionStudent’s t test with Welch’s correction0.98
    pNormal distributionStudent’s t test with Holm’s test0.50
    qNormal distributionStudent’s t test with Holm’s test0.67
    rNormal distributionStudent’s t test with Holm’s test0.26
    sNon-normal distributionMixed-effects model0.08
    tNon-normal distributionMixed-effects model0.47
    uNon-normal distributionFisher’s exact test0.06
    vNon-normal distributionMixed-effects model0.61
    wNon-normal distributionMixed-effects model0.03
    xNon-normal distributionFisher’s exact test0.22
    yNormal distributionANOVAHIF-1αfl/fl vs lysM-Cre:HIF-1αfl/fl = 0.03;HIF-1αfl/fl vs GFAP-Cre:HIF-1αfl/fl = 0.02;lysM-Cre:HIF-1αfl/fl vs GFAP-Cre:HIF-1αfl/fl = 0.03
    • Superscript letters refer to the statistical tests in figures, Results, and Table 1.

Back to top

In this issue

eneuro: 2 (2)
eNeuro
Vol. 2, Issue 2
March/April 2015
  • Table of Contents
  • Index by author
Email

Thank you for sharing this eNeuro article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Hypoxia Inducible Factor-1α in Astrocytes and/or Myeloid Cells Is Not Required for the Development of Autoimmune Demyelinating Disease
(Your Name) has forwarded a page to you from eNeuro
(Your Name) thought you would be interested in this article in eNeuro.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
View Full Page PDF
Citation Tools
Hypoxia Inducible Factor-1α in Astrocytes and/or Myeloid Cells Is Not Required for the Development of Autoimmune Demyelinating Disease
Natacha Le Moan, Kim M. Baeten, Victoria A. Rafalski, Jae Kyu Ryu, Pamela E. Rios Coronado, Catherine Bedard, Catriona Syme, Dimitrios Davalos, Katerina Akassoglou
eNeuro 30 March 2015, 2 (2) ENEURO.0050-14.2015; DOI: 10.1523/ENEURO.0050-14.2015

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Hypoxia Inducible Factor-1α in Astrocytes and/or Myeloid Cells Is Not Required for the Development of Autoimmune Demyelinating Disease
Natacha Le Moan, Kim M. Baeten, Victoria A. Rafalski, Jae Kyu Ryu, Pamela E. Rios Coronado, Catherine Bedard, Catriona Syme, Dimitrios Davalos, Katerina Akassoglou
eNeuro 30 March 2015, 2 (2) ENEURO.0050-14.2015; DOI: 10.1523/ENEURO.0050-14.2015
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Significance Statement
    • Introduction
    • Material and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
    • Synthesis
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Keywords

  • astrocytes
  • Cre/loxP
  • EAE
  • HIF-1alpha
  • macrophages
  • neuroinflammation

Responses to this article

Respond to this article

Jump to comment:

No eLetters have been published for this article.

Related Articles

Cited By...

More in this TOC Section

Negative Results

  • Closed-Loop Acoustic Stimulation Enhances Sleep Oscillations But Not Memory Performance
  • Cyfip1 Haploinsufficiency Does Not Alter GABAA Receptor δ-Subunit Expression and Tonic Inhibition in Dentate Gyrus PV+ Interneurons and Granule Cells
  • Glucagon-Like Peptide-1 Receptor Agonist Treatment Does Not Reduce Abuse-Related Effects of Opioid Drugs
Show more Negative Results

Disorders of the Nervous System

  • Chemogenetic Perturbation of the Posterior But Not Anterior Cerebellum Reduces Voluntary Ethanol Consumption
  • Energy Expenditure Homeostasis Requires ErbB4, an Obesity Risk Gene, in the Paraventricular Nucleus
  • In Utero Electroporated Neurons for Medium-Throughput Screening of Compounds Regulating Neuron Morphology
Show more Disorders of the Nervous System

Subjects

  • Disorders of the Nervous System

  • Home
  • Alerts
  • Visit Society for Neuroscience on Facebook
  • Follow Society for Neuroscience on Twitter
  • Follow Society for Neuroscience on LinkedIn
  • Visit Society for Neuroscience on Youtube
  • Follow our RSS feeds

Content

  • Early Release
  • Current Issue
  • Latest Articles
  • Issue Archive
  • Blog
  • Browse by Topic

Information

  • For Authors
  • For the Media

About

  • About the Journal
  • Editorial Board
  • Privacy Policy
  • Contact
  • Feedback
(eNeuro logo)
(SfN logo)

Copyright © 2023 by the Society for Neuroscience.
eNeuro eISSN: 2373-2822

The ideas and opinions expressed in eNeuro do not necessarily reflect those of SfN or the eNeuro Editorial Board. Publication of an advertisement or other product mention in eNeuro should not be construed as an endorsement of the manufacturer’s claims. SfN does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of any material contained in eNeuro.